First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer

FHS
April 26, 2024
10:42 am

The real-world safety and efficacy of sacituzumab govitecan (SG) against metastatic triple-negative breast cancer.

(Measles + rubella) vaccine by Indian Immunologicals for Rubella (German Measles): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

October 4, 2023

Microbiome Study Provides New Clues to Common Pathology of Inflammatory Conditions

An alteration in gut microbiome diversity occurred in patients with three different inflammatory conditions, suggesting a common pathology, prospective rRNA sequencing of patients’ stool samples

August 9, 2023

Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar

November 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.